Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Clinical Rheumatology
Published in: Clinical Rheumatology 10/2010

01-10-2010 | Case Report

Cerebral tuberculoma in a patient receiving anti-TNF alpha (adalimumab) treatment

Authors: Karen Lynch, Michael Farrell

Published in: Clinical Rheumatology | Issue 10/2010

Login to get access

Abstract

We report a case of a cerebral tuberculoma in a 60-year-old woman with rheumatoid arthritis while receiving the anti-tumor necrosis factor alpha monoclonal antibody, adalimumab (Humira), for active disease. MR brain imaging for dyspraxia revealed a left parietal ring-enhancing lesion, which on resection was shown to be a necrotizing granuloma. There were no associated pulmonary lesions, and the patient was systemically well. Sputum and urine cultures were negative for tuberculosis. The patient was treated with anti-tuberculous medications and made an excellent recovery. We consider this to be the first documented case of tuberculosis involving the central nervous system occurring in the setting of adalimumab treatment.
Literature
1.
Alonso-Ruiz A, Pijoan JI, Ansuategui E, Urkaregi A, Calabozo M, Quintana A (2008) Tumor necrosis factor alpha drugs in rheumatoid arthritis: systemic review and metanalysis of efficacy and safety. BMC Musculoskelet Disord 17(9):52, ReviewCrossRef
2.
Dimakou K, Papaioannides D, Latsi P, Katsimboula S, Korantzopoulos P, Orphanidou D (2004) Disseminated tuberculosis complicating anti-TNF-α treatment. Int J Clin Pract 58(11):1052–1055CrossRefPubMed
3.
Askling J, Fored CM, Brandt L et al (2005) Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden. Arthritis Rheum 52:1986–1992CrossRefPubMed
4.
Bongartz T, Sutton AJ, Sweeting MJ et al (2006) Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 295(19):2275–2285CrossRefPubMed
5.
Furst DE, Schiff MH, Fleischmann RM et al (2003) Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). J Rheumatol 30(12):2563–2571PubMed
6.
Keane J, Gershon S et al (2001) Tuberculosis associated with infliximab, a tumor necrosis factor-neutralizing agent. N Engl J Med 345:1098–1104CrossRefPubMed
7.
Raval A, Akhavan-Toyserkani G et al (2007) Brief communication: characteristics of spontaneous cases of tuberculosis associated with infliximab. Ann Intern Med 147:699PubMed
8.
Ubukata M et al (2005) Pulmonary TB with cerebellar lesion in a patient after anti-TNF alpha (infliximab) treatment for rheumatoid arthritis. Nihon Kokyuki Gakkai Zasshi 43(4):247–51, Article in JapanesePubMed
9.
Fonscea JE, Canhao H, Silva C et al (2006) Tuberculosis in rheumatic patients treated with tumor necrosis alpha antagonists: the Portuguese experience. Acta Reumatol Port 31:247–253
10.
Schiff et al (2006) Safety analyses of adalimumab (Humira) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis. Ann Rheum Dis 65:889–894CrossRef
11.
Carmona L, Gomez-Reino JJ, Rodriguez-Valverde V et al (2005) Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. Arthritis Rheum 52:1766–1772CrossRefPubMed
12.
13.
Pai M, Flores L et al (2003) Diagnostic accuracy of nucleic acid amplification tests for tuberculous meningitis: a systematic review and meta-analysis. Lancet Infect Dis 3:633–643CrossRefPubMed
14.
Sumi MG, Mathai A et al (2001) Diagnostic utility of polymerase chain reaction and immunohistochemical techniques for the laboratory diagnosis of intracranial tuberculoma. Clin Neuropathol 20:176–180PubMed
15.
Thwaites GE, Nguyen DB et al (2004) Dexamethasone for the treatment of tuberculous meningitis in adolescents and adults. N Engl J Med 351:1741–1751CrossRefPubMed
Metadata
Title
Cerebral tuberculoma in a patient receiving anti-TNF alpha (adalimumab) treatment
Authors
Karen Lynch
Michael Farrell
Publication date
01-10-2010
Publisher
Springer-Verlag
Published in
Clinical Rheumatology / Issue 10/2010
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-010-1466-7

Other articles of this Issue 10/2010

Clinical Rheumatology 10/2010 Go to the issue

Brief Report

Analysis of clinical manifestations and pathology of lupus nephritis: a retrospective review of 82 cases

Original Article

Constitutional symptoms at the onset of rheumatoid arthritis and subsequent arterial stiffness

Case Report

Etanercept-refractory adult-onset Still’s disease with thrombotic thrombocytopenic purpura successfully treated with tocilizumab

Original Article

Does exercise affect the antioxidant system in patients with ankylosing spondylitis?

Brief Report

An open-label pilot study of the efficacy and safety of anakinra in patients with psoriatic arthritis refractory to or intolerant of methotrexate (MTX)

Case Report

May anakinra be used earlier in adult onset Still disease?
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits